Vaginal fungus: causes and treatment of candidiasis

Vulvovaginal candidiasis — commonly referred to as a yeast infection — is one of the most common gynecologic conditions encountered in outpatient care. While it is rarely life‑threatening, symptomatic infection can cause significant discomfort, interfere with daily activities and sexual function, and recur in a subset of patients. Timely recognition, accurate diagnosis, and appropriate treatment are essential to relieve symptoms, minimize recurrence, and avoid unnecessary or ineffective therapies.

This article reviews the pathophysiology, risk factors, clinical presentation, diagnostic approach, management strategies (including special populations), prevention measures, and when to seek medical attention. Recommendations are based on established clinical guidance and mainstream medical references (American College of Obstetricians and Gynecologists, National Institutes of Health/MedlinePlus, Mayo Clinic, Cleveland Clinic).

What is vulvovaginal candidiasis?

Vulvovaginal candidiasis (VVC) is an infection of the vulva and vagina caused by yeast from the genus Candida. Candida albicans accounts for the majority of cases, but other species (for example, Candida glabrata, Candida parapsilosis) may be responsible, especially in recurrent or treatment‑resistant infections (Cleveland Clinic; Mayo Clinic).

Candida species are part of the normal vaginal microbiota in many people and coexist with bacteria and other microorganisms. Infection typically results from an overgrowth of Candida that occurs when the natural balance of the vaginal ecosystem is disrupted, or when host defense mechanisms are compromised. The degree of fungal proliferation and the host inflammatory response determine the severity of symptoms.

(References: American College of Obstetricians and Gynecologists; MedlinePlus/NIH; Mayo Clinic; Cleveland Clinic)

Vaginal microbiome and host defenses

A healthy vaginal ecosystem is characterized by a predominance of lactobacilli, low vaginal pH (typically <4.5), and intact mucosal immunity. Lactobacilli produce lactic acid and hydrogen peroxide, creating an acidic environment that limits overgrowth of opportunistic organisms, including Candida.

Factors that alter vaginal pH, reduce lactobacilli populations, or impair local immunity increase susceptibility to candidiasis. Estrogen levels influence vaginal epithelial thickness and glycogen content, which in turn affect the vaginal microbiota — this is why pregnancy and certain hormonal states can predispose to infection. Systemic conditions such as poorly controlled diabetes impair innate and adaptive immune responses and provide increased substrate (glucose) for fungal growth.

(References: ACOG Practice and patient education materials; MedlinePlus)

Causes and risk factors

VVC results from a combination of organism presence and conditions permissive to overgrowth. Common risk factors include:

Recent or broad‑spectrum antibiotic use: antibiotics can reduce protective lactobacilli, allowing Candida to proliferate.
Elevated estrogen states: pregnancy, high‑dose estrogen therapy, and the menstrual cycle may increase susceptibility.
Uncontrolled diabetes mellitus: hyperglycemia is associated with increased Candida colonization and recurrent infection.
Immunosuppression: HIV infection, systemic corticosteroid use, cytotoxic chemotherapy and other immunosuppressive therapies raise the risk of more severe or recurrent disease.
Tight, non‑breathable clothing or prolonged dampness: occlusive garments or prolonged exposure to moisture can create an environment favorable to Candida growth.
Intravaginal products and douching: these can disrupt normal flora and local defenses.
High‑dose or frequent topical steroid use in the vulvar area: can exacerbate fungal growth and thin the skin.
Recurrent episodes may be idiopathic or associated with persistent behavioral, metabolic, or medication‑related factors.

While dietary sugar and food choices are sometimes implicated by patients, evidence for a direct causal relationship between dietary sugar and VVC is limited. Similarly, routine treatment of asymptomatic male sexual partners is not recommended unless they are symptomatic.

(References: ACOG; Mayo Clinic; Cleveland Clinic; MedlinePlus/NIH)

Clinical presentation

Typical symptoms of uncomplicated VVC include:

Vulvar and vaginal pruritus (itching), often intense.
Vulvar irritation, burning or soreness.
Vaginal discharge that is typically described as thick and white with a curd‑like or "cottage‑cheese" appearance; however, discharge characteristics are not specific.
Dysuria limited to superficial burning with urination may occur.
Pain or discomfort with sexual activity can be present due to vulvar inflammation.

On physical examination, findings may include erythema and edema of the vulvar and vestibular tissues, fissuring of the vulvar skin in severe cases, and white adherent vaginal discharge. Vaginal pH is usually normal (<4.5) in candidiasis, which helps distinguish it from bacterial vaginosis or trichomoniasis.

Severity is often categorized as mild-to-moderate versus severe; severe cases manifest with marked erythema, fissures, significant edema and substantial discomfort. Recurrent VVC is typically defined as four or more symptomatic episodes in a 12‑month period.

(References: ACOG; Mayo Clinic; Cleveland Clinic)

Diagnostic approach

Many cases of VVC are diagnosed and treated empirically based on typical symptoms and examination findings. However, laboratory testing is recommended when features are atypical, when there is treatment failure, for recurrent episodes, or when another diagnosis (for example, bacterial vaginosis, trichomoniasis, dermatologic conditions) is suspected.

Diagnostic tools include:

Vaginal pH testing: values <4.5 are consistent with candidiasis, while higher pH suggests other causes.
Microscopy of vaginal secretions: a wet mount (saline) and potassium hydroxide (KOH) preparation can identify budding yeast, pseudohyphae or hyphae. A KOH test can cause clearing of debris and reveal yeast structures.
Fungal culture: useful in recurrent or refractory cases and for species identification, particularly when non‑albicans species are suspected (these may respond differently to therapy).
Nucleic acid amplification tests (NAAT) or PCR assays: some assays can detect Candida DNA and may be useful in selected cases, though availability and indications vary.
Biopsy: rarely necessary, reserved for suspected dermatologic conditions or persistent lesions where malignancy or other pathologies must be excluded.

ACOG recommends laboratory confirmation when the diagnosis is uncertain or when symptoms persist despite appropriate therapy. Empiric therapy without testing may be reasonable for classic presentations in patients with prior documented VVC and a reliable response to treatment.

(References: ACOG; MedlinePlus/NIH; Mayo Clinic)

Differential diagnosis

Conditions that can mimic VVC include:

Bacterial vaginosis: often presents with thin, homogenous, malodorous discharge and elevated vaginal pH; microscopy shows clue cells.
Trichomonas vaginalis infection: typically causes frothy, sometimes malodorous discharge, and a pH >4.5; motile trichomonads may be seen on wet mount.
Contact or irritant dermatitis: often related to topical products, soaps, or laundry detergents; may cause itching and vulvar erythema without discharge.
Vulvar dermatoses: lichen sclerosus, lichen simplex chronicus, and allergic reactions can produce pruritus and vulvar skin changes.
Atrophic vaginitis (postmenopausal): low estrogen leads to thin, pale mucosa, dryness and dyspareunia rather than discharge typical of candidiasis.
Sexually transmitted infections: some STIs can present with vulvar symptoms and should be considered based on exposure risk and symptoms.

Distinguishing features on history, exam and laboratory testing guide appropriate management.

(References: ACOG; Mayo Clinic; Cleveland Clinic)

Treatment of uncomplicated vaginal candidiasis

Management differs between uncomplicated and complicated cases. Uncomplicated VVC typically involves sporadic, mild‑to‑moderate infection in a nonpregnant, immunocompetent person, with infection caused by Candida albicans.

First‑line treatments for uncomplicated VVC:

Topical azole antifungals (azole vaginal creams, suppositories or tablets): clotrimazole, miconazole, and tioconazole are commonly used. Treatment regimens vary from a single dose to 1–7 days depending on formulation and concentration. Topical therapy is effective and commonly used in clinical practice (Mayo Clinic; CDC guidance).
Oral fluconazole: a single 150 mg oral dose is an effective alternative for many patients with uncomplicated VVC, especially when topical administration is not acceptable. Oral therapy has systemic exposure and potential drug interactions; it should be used with caution in patients with significant liver disease or who are taking interacting medications.

Choice between topical and oral therapy depends on patient preference, prior response to therapy, medication tolerability, pregnancy status and potential drug interactions.

(References: Mayo Clinic; Cleveland Clinic; ACOG)

Treatment considerations and cautions

Pregnancy: topical azole therapy (vaginal formulations) is the preferred treatment during pregnancy. Oral fluconazole is generally avoided, particularly repeated or high‑dose regimens, due to evidence suggesting potential teratogenic risks with prolonged systemic exposure; a single dose may be considered in certain circumstances after counseling (Mayo Clinic; ACOG).
Severe infection: in cases of severe VVC, longer courses of topical azole therapy or repeated oral fluconazole doses (for example, 150 mg every 72 hours for 2–3 doses) may be necessary.
Hepatic impairment: fluconazole is metabolized by the liver; caution is advised in patients with significant hepatic disease.
Drug interactions: fluconazole has multiple potential interactions (e.g., with certain anticoagulants, statins, and other agents) and should be prescribed with consideration of a patient’s medication list.

(References: ACOG; Mayo Clinic; Cleveland Clinic)

Management of complicated and recurrent candidiasis

Complicated VVC includes any of the following: severe infection, recurrent episodes (≥4 per year), infection caused by non‑albicans Candida species, infection in the immunocompromised patient, or infection during pregnancy.

Management strategies:

Recurrent VVC: commonly managed with an induction regimen followed by suppressive therapy. A frequently used protocol is oral fluconazole 150 mg every 72 hours for three doses (induction), followed by 150 mg once weekly for 6 months for suppression. Individualized regimens may be necessary for treatment failure or intolerance (ACOG; clinical guidelines).
Non‑albicans species: Candida glabrata and other non‑albicans species may be less responsive to fluconazole. Vaginal boric acid (600 mg intravaginally once daily for 14 days) has demonstrated efficacy for refractory or non‑albicans infections; boric acid is potentially caustic and should never be used orally or during pregnancy. Nystatin vaginal tablets or topical amphotericin B may be alternatives in selected cases. Culture and species identification help guide therapy.
Immunocompromised patients: these individuals may require longer or systemic therapy and referral to a specialist if infections are severe, recurrent, or associated with systemic signs.

Close follow‑up is important to confirm resolution and to evaluate for underlying contributing factors (for example, uncontrolled diabetes, medication changes, or immunosuppression).

(References: ACOG; Cleveland Clinic; Mayo Clinic)

Non‑prescription therapies and complementary approaches

Over‑the‑counter (OTC) topical azoles are effective for many patients with uncomplicated VVC. It is important that patients follow product instructions and select a regimen appropriate for symptom severity.

Other measures commonly used by patients include probiotic supplements, topical applications (yogurt), or dietary modifications. The evidence for probiotics and diet in preventing or treating VVC is mixed and not definitive; some studies suggest modest benefit from certain probiotic strains, but high‑quality randomized data are limited. Patients should be advised that unproven remedies may delay effective therapy and that consultations with a clinician are warranted for recurrent or severe symptoms.

(References: Mayo Clinic; MedlinePlus/NIH)

Special populations

Pregnancy

VVC is common during pregnancy due to hormonal changes. Topical azole therapy applied intravaginally is the preferred treatment in pregnancy; oral fluconazole is generally avoided because repeated or high doses have been associated with rare birth defects. Any pregnant person with suspected VVC should seek evaluation and discuss safe treatment options with their clinician.

(References: ACOG; Mayo Clinic)

Diabetes mellitus

Poor glycemic control increases the risk of candidal overgrowth and recurrent infections. Optimizing blood glucose control is a key component of management in these patients. Clinicians should screen for and address hyperglycemia in patients presenting with recurrent VVC.

(References: NIH/MedlinePlus; Cleveland Clinic)

Immunocompromised individuals

People with HIV or who are receiving immunosuppressive therapies may experience more frequent, severe or persistent VVC. These cases may require systemic therapy, longer courses of antifungals, and collaboration with infectious disease specialists. Prophylactic antifungal therapy is not routinely recommended but may be considered in select scenarios.

(References: ACOG; CDC guidance)

Prevention strategies

Primary prevention focuses on minimizing modifiable risk factors:

Avoid unnecessary antibiotic use and discuss indications with the prescribing clinician.
Maintain good vulvar hygiene: gentle cleansing with water or mild, fragrance‑free cleansers; avoid douching and scented products that can disrupt the microbiome.
Wear breathable, cotton underwear and avoid prolonged use of damp or occlusive clothing (for example, wetsuits, tight workout leggings for long periods).
Change out of wet bathing suits or sweaty exercise clothing promptly.
Avoid intravaginal products unless medically indicated.
Optimize control of underlying conditions such as diabetes.
Consider reviewing hormonal contraceptive choices with a clinician if recurrent episodes coincide with estrogen therapy, recognizing that hormonal factors may play a role.

There is no universal recommendation for routine probiotic use for prevention; some individuals may find benefit, but evidence is inconsistent. Clinicians should discuss the limited evidence and potential costs with patients.

(References: Mayo Clinic; Cleveland Clinic; ACOG)

When to seek medical attention

Seek prompt medical evaluation if any of the following occur:

Severe vulvar pain, significant swelling or extensive fissuring.
Systemic symptoms such as fever.
First episode of suspected vulvovaginal infection when diagnosis is uncertain.
Recurrent episodes (four or more per year) or episodes that do not respond to appropriate treatment.
Pregnancy with suspected infection.
Symptoms in a person with immunosuppression or poorly controlled diabetes.
Any genital lesion or symptom that raises concern for other conditions.

Appropriate evaluation helps confirm the diagnosis, rule out other causes, and guide effective therapy.

(References: ACOG; Mayo Clinic; MedlinePlus/NIH)

Potential complications

Uncomplicated VVC generally resolves with appropriate therapy and seldom leads to severe complications in immunocompetent individuals. However, complications can occur:

Persistent or recurrent symptomatic infections that impair quality of life.
Secondary skin breakdown, fissures, or bacterial superinfection if severe inflammation is untreated.
In immunocompromised individuals, localized infection can be more severe and systemic candidiasis is possible, although rare.
In pregnancy, symptomatic infections can cause significant discomfort and warrant treatment. Repeated systemic azole exposure has potential fetal risks and should be managed in consultation with obstetric care.

(References: ACOG; Cleveland Clinic)

Myths and frequently asked questions

Is candidiasis a sexually transmitted infection?
Candida is not considered a classic sexually transmitted infection. It commonly represents overgrowth of organisms that are already part of the genital flora. Sexual activity can sometimes precipitate or transmit Candida between partners, but routine treatment of asymptomatic partners is not generally recommended.

Can you have intercourse during an active infection?
Sexual activity may be uncomfortable and is best avoided until symptoms resolve. Barrier methods and treating symptomatic partners may be considered if symptoms persist after appropriate therapy, but treatment of male partners is typically reserved for symptomatic cases.

Are over‑the‑counter treatments safe and effective?
OTC topical azole agents are effective for many patients with uncomplicated VVC. Accurate self‑diagnosis can be difficult; if symptoms are atypical or fail to respond to OTC therapy, a clinician evaluation and laboratory testing are advised.

Do probiotics prevent yeast infections?
Evidence is mixed. Some studies show modest benefit for certain probiotic strains, but robust clinical recommendations cannot be made at present. Probiotics are not a substitute for antifungal therapy when treatment is indicated.

(References: Mayo Clinic; Cleveland Clinic; MedlinePlus/NIH)

Practical counseling points for clinicians

Confirm the diagnosis when feasible, particularly for recurrent or atypical presentations.
Tailor therapy to the patient’s clinical scenario, pregnancy status, comorbidities and drug interactions.
Counsel patients about realistic expectations: symptoms may take several days to fully resolve after initiation of therapy.
Discuss preventive measures and review modifiable risk factors (antibiotics, tight clothing, glycemic control).
For recurrent VVC, evaluate for diabetes, medication exposures and immunosuppression; consider culture and species identification to guide therapy.
Provide clear instructions on the correct use of topical formulations and the importance of completing prescribed regimens.

(References: ACOG; Cleveland Clinic; Mayo Clinic)

Summary

Vulvovaginal candidiasis is a common and generally treatable condition caused by overgrowth of Candida species in the vulvovaginal environment. Typical symptoms include vulvar itching, irritation and a thick white discharge. Diagnosis can often be made clinically, but laboratory confirmation is important in atypical, recurrent or treatment‑resistant cases. First‑line therapy for uncomplicated VVC includes topical azole antifungals or a single oral dose of fluconazole; complicated or recurrent infections require longer or alternative regimens and may necessitate specialist input. Pregnant people, those with recurrent episodes, or individuals with immunosuppression warrant particular attention. Prevention focuses on reducing identifiable risk factors, avoiding unnecessary intravaginal products and treating underlying medical issues such as uncontrolled diabetes.

For additional reliable patient information and clinician resources, consult:

American College of Obstetricians and Gynecologists (ACOG) patient education and practice guidance (https://www.acog.org)
MedlinePlus/NIH: Vaginal yeast infections (https://medlineplus.gov/yeastinfections.html)
Mayo Clinic: Vaginal yeast infection overview (https://www.mayoclinic.org)
Cleveland Clinic: Yeast infection (vaginal) (https://my.clevelandclinic.org)

If you experience persistent, recurrent, or severe symptoms, make an appointment with a healthcare professional for evaluation and individualized care.